GlobalData on MSN
MHRA outlines upcoming IVD submission shift for clinical trials
From 28 April, IVDs used clinical trials will be subject to an upfront assessment by the MHRA as part of a Clinical Trial of ...
Miriam Dervan, founder & CEO of mdgroup, explains how treating patient experience as a strategic investment—rather than a ...
Researchers at Mount Sinai launch a new AI platform to match more cancer patients with clinical trials, aiming to expand enrolment.
Over recent decades, advances in cancer treatment have yielded substantial improvements in patient outcomes, driving up survival, and even rendering some cancers curable. These advances have been ...
During the discussion, he explained what he wants patients to understand about participating in clinical trials for their gastrointestinal cancers. Additionally, he imparted key updates from this ...
The oncolytic virus therapy landscape has expanded steadily over the past decade, with over 100 companies worldwide pursuing clinical or preclinical programs. A few leaders, such as Candel ...
In the first of a two-parter, lawyers at Santarelli analyse the patentability of therapeutic inventions where publication of ...
When news breaks, you need to understand what actually matters. At Vox, our mission is to help you make sense of the world — and that work has never been more vital. But we can’t do it on our own. We ...
There are currently dozens of clinical trials examining new ways to treat mantle cell lymphoma (MCL). People can learn about trial recruitment at ClinicalTrials.gov. Research into mantle cell lymphoma ...
SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that an analyst research report was published on the Company that explains ...
SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that an analyst research report was published on the Company that explains ...
AUSTIN, Texas, Nov. 22, 2024 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (PSTV) (Nasdaq: PSTV) (“Plus” or the “Company”), will present data from ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果